{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:01:20Z","timestamp":1791050480268,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clinre.2025.102530","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T02:38:01Z","timestamp":1736563081000},"page":"102530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessing the efficacy of farnesoid X receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"49","author":[{"given":"Jai","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Mohsin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba Hussain","family":"Alzaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tripti","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-0189","authenticated-orcid":false,"given":"Adeena","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi Krishna","family":"Lavu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarwan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clinre.2025.102530_bib0001","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102530_bib0002","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9734560","article-title":"Chicoric acid ameliorates nonalcoholic fatty liver disease via the AMPK\/Nrf2\/NF\u03baB signaling pathway and restores gut microbiota in high-fat-diet-fed mice","author":"Ding","year":"2020","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.clinre.2025.102530_bib0003","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/apt.17158","article-title":"Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world","volume":"56","author":"Henry","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.clinre.2025.102530_bib0004","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.clinre.2025.102530_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"22","key":"10.1016\/j.clinre.2025.102530_bib0006","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1001\/archinte.159.22.2647","article-title":"The continuing importance of bile acids in liver and intestinal disease","volume":"159","author":"Hofmann","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1-3","key":"10.1016\/j.clinre.2025.102530_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2004.06.001","article-title":"Mitochondrially-mediated toxicity of bile acids","volume":"203","author":"Palmeira","year":"2004","journal-title":"Toxicology"},{"issue":"5","key":"10.1016\/j.clinre.2025.102530_bib0008","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1074\/jbc.M804585200","article-title":"Bile acid-induced apoptosis in hepatocytes is caspase-6-dependent","volume":"284","author":"Rust","year":"2009","journal-title":"J Biol Chem"},{"issue":"14","key":"10.1016\/j.clinre.2025.102530_bib0009","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3748\/wjg.15.1677","article-title":"Bile-acid-induced cell injury and protection","volume":"15","author":"Perez","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102530_bib0010","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.livres.2020.05.001","article-title":"Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis","volume":"4","author":"Chiang","year":"2020","journal-title":"Liver Res"},{"issue":"5","key":"10.1016\/j.clinre.2025.102530_bib0011","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2025.102530_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the treatment of NASH-two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.clinre.2025.102530_bib0013","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2025.102530_bib0014","doi-asserted-by":"crossref","unstructured":"Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial [published correction appears in Lancet. 2015;385(9972):946] [published correction appears in Lancet. 2016 Apr 16;387(10028):1618]. Lancet. 2015;385(9972):956-965. 10.1016\/S0140-6736(14)61933-4.","DOI":"10.1016\/S0140-6736(14)61933-4"},{"issue":"2","key":"10.1016\/j.clinre.2025.102530_bib0015","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clinre.2025.102530_bib0016","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clinre.2025.102530_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies","volume":"291","author":"Lee","year":"2022","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.clinre.2025.102530_bib0018","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","article-title":"Association of nonalcoholic fatty liver disease with insulin resistance","volume":"107","author":"Marchesini","year":"1999","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.clinre.2025.102530_bib0019","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.clinre.2025.102530_bib0020","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41580-018-0093-z","article-title":"Adipogenesis and metabolic health","volume":"20","author":"Ghaben","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.clinre.2025.102530_bib0021","doi-asserted-by":"crossref","first-page":"282","DOI":"10.37349\/edd.2023.00031","article-title":"Therapeutic targets for metabolic dysfunction-associated steatotic liver disease and their roles in hepatocellular carcinoma","volume":"2","author":"Wei","year":"2023","journal-title":"Explor Dig Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clinre.2025.102530_bib0022","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.clinre.2015.06.012","article-title":"Inflammasome activation in the liver: Focus on alcoholic and non-alcoholic steatohepatitis","volume":"39","author":"Szabo","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102530_bib0023","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/hep.26081","article-title":"Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice","volume":"57","author":"Miura","year":"2013","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2025.102530_bib0024","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2007.04.019","article-title":"Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis","volume":"47","author":"Rivera","year":"2007","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102530_bib0025","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.03.052","article-title":"Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice","volume":"139","author":"Miura","year":"2010","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.clinre.2025.102530_bib0026","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/liv.12537","article-title":"Both bone marrow-derived and non-bone marrow-derived cells contribute to AIM2 and NLRP3 inflammasome activation in a MyD88-dependent manner in dietary steatohepatitis","volume":"34","author":"Csak","year":"2014","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.clinre.2025.102530_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s43440-019-00020-1","article-title":"New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis","volume":"72","author":"Pydyn","year":"2020","journal-title":"Pharmacol Rep"},{"issue":"4","key":"10.1016\/j.clinre.2025.102530_bib0028","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cld.708","article-title":"An update on the pharmacological treatment of nonalcoholic fatty liver disease: beyond lifestyle modifications","volume":"11","author":"Alkhouri","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"11","key":"10.1016\/j.clinre.2025.102530_bib0029","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/nrgastro.2013.171","article-title":"The global NAFLD epidemic","volume":"10","author":"Loomba","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2025.102530_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166133","article-title":"FXR in liver physiology: Multiple faces to regulate liver metabolism","volume":"1867","author":"Panzitt","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.clinre.2025.102530_bib0031","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.12.007","article-title":"Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules","volume":"104","author":"Copple","year":"2016","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.clinre.2025.102530_bib0032","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/01.ATV.0000178994.21828.a7","article-title":"The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism","volume":"25","author":"Claudel","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102530_bib0033","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/aps.2014.116","article-title":"Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis","volume":"36","author":"Jiao","year":"2015","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"10.1016\/j.clinre.2025.102530_bib0034","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/biomedicines10020274","article-title":"Pharmacotherapy for non-alcoholic fatty liver disease: emerging targets and drug candidates","volume":"10","author":"Prikhodko","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.clinre.2025.102530_bib0035","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1021\/jm8014124","article-title":"Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR)","volume":"52","author":"Flatt","year":"2009","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.clinre.2025.102530_bib0036","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.clinre.2025.102530_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102227","article-title":"Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis","volume":"47","author":"Jang","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102530_bib0038","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the american association for the study of liver diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.clinre.2025.102530_bib0039","first-page":"83","article-title":"Diagnostic and treatment implications of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"15","author":"Wong","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"5","key":"10.1016\/j.clinre.2025.102530_bib0040","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s11095-013-0986-7","article-title":"Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance","volume":"30","author":"Ma","year":"2013","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.clinre.2025.102530_bib0041","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102530_bib0042","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"issue":"9-10","key":"10.1016\/j.clinre.2025.102530_bib0043","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00508-020-01735-5","article-title":"Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease","volume":"133","author":"Traussnigg","year":"2021","journal-title":"Wien Klin Wochenschr"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T10:25:56Z","timestamp":1741256756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2210740125000105"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102530","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the efficacy of farnesoid X receptor agonists in the management of metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102530"}}